BioNTech (UK) Management Evaluation
| 0A3M Stock | USD 118.55 0.15 0.13% |
BioNTech employs about 5.5 K people. The company is managed by 10 executives with a total tenure of roughly 12834 years, averaging almost 1283.0 years of service per executive, having 550.0 employees per reported executive. Inspection of BioNTech's management performance can provide insight into the company performance.
| Jens Holstein Insider CFO Board |
| Oliver Hennig VP VP Operations |
BioNTech |
BioNTech Management Team Effectiveness
The company has return on total asset (ROA) of 0.1692 % which means that it generated a profit of $0.1692 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2382 %, meaning that it generated $0.2382 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Non Currrent Assets Other are quite stable compared to the past year. Intangible Assets is expected to rise to about 844.3 M this year, although the value of Total Assets will most likely fall to about 12.1 B.Common Stock Shares Outstanding is expected to rise to about 260.6 M this year. Net Income Applicable To Common Shares is expected to rise to about 12.4 B this year
BioNTech Workforce Comparison
BioNTech SE is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 33,701. BioNTech retains roughly 5,500 in number of employees claiming about 16% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.48 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.64 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.64. BioNTech SE Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. BioNTech SE Price Series Summation is a cross summation of BioNTech price series and its benchmark/peer.
BioNTech Notable Stakeholders
A BioNTech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioNTech often face trade-offs trying to please all of them. BioNTech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioNTech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pr MD | CoFounder Board | Profile | |
| Oliver Hennig | VP Operations | Profile | |
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | VP Strategy | Profile | |
| James Ryan | Chief Board | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Ryan Richardson | MD Officer | Profile | |
| Sierk Poetting | COO MD | Profile | |
| Ozlem MD | Chief CoFounder | Profile | |
| Sean Marett | Chief Officer | Profile |
About BioNTech Management Performance
The success or failure of an entity such as BioNTech SE often depends on how effective the management is. BioNTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioNTech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioNTech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Japan and is traded on IOB. It employs 2500 people.
BioNTech Workforce Analysis
Traditionally, organizations such as BioNTech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioNTech within its industry.BioNTech Manpower Efficiency
Return on BioNTech Manpower
| Revenue Per Employee | 694.4K | |
| Revenue Per Executive | 381.9M | |
| Net Income Per Employee | 169.1K | |
| Net Income Per Executive | 93M | |
| Working Capital Per Employee | 3.2M | |
| Working Capital Per Executive | 1.7B |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..